Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Medical Sains : Jurnal Ilmiah Kefarmasian Medical Sains : Jurnal Ilmiah Kefarmasian
Umar Santosa
Regional public hospital 45 Kuningan
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
COST-EFFECTIVENESS ANALYSIS OF ANTICOAGULANT USAGE IN COVID-19 PATIENTS AT 45 KUNINGAN HOSPITAL Juju Jumiati; Yusi Anggriani; Yati Sumiati; Umar Santosa
Medical Sains : Jurnal Ilmiah Kefarmasian Vol 8 No 4 (2023): Forthcoming Issue
Publisher : Sekolah Tinggi Farmasi Muhammadiyah Cirebon

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37874/ms.v8i4.892

Abstract

Cost-effectiveness analysis (CEA) is a pharmacoeconomic method that compares prices from all sources consumed (cost) with the outcome value of a program or intervention to obtain objective answers to the selection of drugs that are effective in terms of benefits and costs. COVID-19, or Coronavirus Disease 2019, is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) and causes acute respiratory distress, including fever, coughing, and shortness of breath. Fondaparinux, aside from heparin and enoxaparin, can be given as an anticoagulant therapeutic option in hospitalized COVID-19 patients, according to the third edition of the COVID-19 care recommendations. This study aimed to find the most cost-effective therapy among heparin, enoxaparin, and fondaparinux in COVID-19 patients at the RSUD’45 Kuningan. It also applied descriptive non-experimental research methods with retrospectively collected data. The intervention that had been studied was the administration of anticoagulant medication, where the effectiveness of the drug was observed in the reduction of D-dimer levels to normal levels. Meanwhile, the costs were observed from the perspective of a healthcare provider, specifically the RSUD’45 Kuningan. The study sample included 107 patients, with 13 receiving heparin, 41 receiving enoxaparin, and 53 receiving fondaparinux. Bivariate analysis using the chi-square test revealed no significant difference between the drug groups in the proportion of patients who improved and did not improve (sig. value = 0.610)...
COST-EFFECTIVENESS ANALYSIS OF ANTICOAGULANT USAGE IN COVID-19 PATIENTS AT 45 KUNINGAN HOSPITAL Juju Jumiati; Yusi Anggriani; Yati Sumiyati; Umar Santosa
Medical Sains : Jurnal Ilmiah Kefarmasian Vol 8 No 4 (2023)
Publisher : Sekolah Tinggi Farmasi Muhammadiyah Cirebon

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37874/ms.v8i4.892

Abstract

Cost-effectiveness analysis (CEA) is a pharmacoeconomic method that compares prices from all sources consumed (cost) with the outcome value of a program or intervention to obtain objective answers to the selection of drugs that are effective in terms of benefits and costs. COVID-19, or Coronavirus Disease 2019, is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) and causes acute respiratory distress, including fever, coughing, and shortness of breath. Fondaparinux, aside from heparin and enoxaparin, can be given as an anticoagulant therapeutic option in hospitalized COVID-19 patients, according to the third edition of the COVID-19 care recommendations. This study aimed to find the most cost-effective therapy among heparin, enoxaparin, and fondaparinux in COVID-19 patients at the RSUD’45 Kuningan. It also applied descriptive non-experimental research methods with retrospectively collected data. The intervention that had been studied was the administration of anticoagulant medication, where the effectiveness of the drug was observed in the reduction of D-dimer levels to normal levels. Meanwhile, the costs were observed from the perspective of a healthcare provider, specifically the RSUD’45 Kuningan. The study sample included 107 patients, with 13 receiving heparin, 41 receiving enoxaparin, and 53 receiving fondaparinux. Bivariate analysis using the chi-square test revealed no significant difference between the drug groups in the proportion of patients who improved and did not improve (sig. value = 0.610)...
Co-Authors Juju Jumiati Yati Sumiati Yati Sumiyati Yusi Anggriani